PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Chapurlat, Roland
TI  - Effects of Odanacatib in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
DP  - 2012  01
TA  - MD Conference Express
PG  - 21--21
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/21.1.short
4100  - http://mdc.sagepub.com/content/12/19/21.1.full
AB  - Odanacatib is a selective, potent, and reversible cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This article discusses results of A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated with Alendronate. The trial found odanacatib to be safe and effective for increasing bone mineral density in postmenopausal women previously treated with alendronate.